CohBar, Inc. (CWBR) Stock Analysis

CohBar, Inc. (CWBR) Healthcare & Pipeline Overview

CohBar, Inc., a clinical-stage biotechnology company, specializes in developing mitochondria-based therapeutics (MBTs) targeting chronic and age-related diseases. Their lead candidate, CB4211, is undergoing clinical trials for NASH and obesity, positioning CohBar within the competitive biotechnology landscape focused on innovative therapeutic solutions.

What Is the Investment Thesis for CWBR?

CohBar's investment thesis centers on its innovative approach to developing mitochondria-based therapeutics (MBTs) for chronic and age-related diseases. The company's lead clinical candidate, CB4211, targeting NASH and obesity, represents a significant value driver. Positive Phase Ib trial results could lead to further clinical development and potential partnerships. Preclinical programs, including CB5138 for fibrotic diseases and CB5064 for COVID-19 associated ARDS, offer additional upside potential. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and competition from other biotechnology companies. With a market cap of $1.19M and a beta of 1.38, CohBar's stock exhibits volatility. Successful execution of its clinical programs and strategic partnerships are crucial for realizing its long-term value. The absence of a dividend reflects its focus on reinvesting capital into research and development.

Based on FMP financials and quantitative analysis

CWBR Key Highlights

Lead clinical candidate CB4211 is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity.

• Focus on mitochondria-based therapeutics (MBTs) provides a novel approach to treating chronic and age-related diseases.
• Preclinical programs include CB5138 analogs for fibrotic diseases and CB5064 analogs for COVID-19 associated ARDS, expanding the pipeline.
• Market capitalization of $1.19M reflects the company's early stage and potential for growth.
• Beta of 1.38 indicates higher volatility compared to the overall market.

Who Are CWBR's Competitors?

CWBR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CWBR's Key Strengths?

Novel mitochondria-based therapeutics (MBTs) platform.

• Lead clinical candidate CB4211 targeting NASH and obesity.
• Experienced management team with expertise in drug development.
• Strong intellectual property portfolio.

What Are CWBR's Weaknesses?

Early-stage clinical development with high risk of failure.

• Limited financial resources.
• Small number of employees.
• Dependence on external funding and partnerships.

What Could Drive CWBR Stock Higher?

Phase Ib clinical trial results for CB4211 in NASH and obesity.

• Advancement of preclinical programs for fibrotic diseases and COVID-19 associated ARDS.
• Potential for strategic partnerships with larger pharmaceutical companies.
• Expansion of the pipeline with new MBTs.

What Are the Key Risks for CWBR?

Financial-distress signal — its Altman Z-Score of -13.78 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-58.4%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures and regulatory setbacks.
• Competition from other biotechnology and pharmaceutical companies.
• Difficulty in raising capital.
• Changes in the regulatory landscape.

What Are the Growth Opportunities for CWBR?

• Growth opportunity 1: Successful completion of the Phase Ia/Ib clinical trial for CB4211 in NASH and obesity could unlock significant value. Positive trial results would pave the way for Phase II and Phase III trials, potentially leading to regulatory approval and commercialization. The timeline for potential commercialization is dependent on clinical trial outcomes and regulatory review, but could be within 3-5 years.
• Growth opportunity 2: Advancing preclinical programs, such as CB5138 for fibrotic diseases and CB5064 for COVID-19 associated ARDS, represents another growth opportunity. Fibrotic diseases, including idiopathic pulmonary fibrosis, affect millions of people worldwide, creating a significant unmet medical need. Successful development of CB5138 could lead to a valuable therapeutic option for these patients. The timeline for these programs is longer, potentially 5-7 years before commercialization.
• Growth opportunity 3: Strategic partnerships with larger pharmaceutical companies could provide CohBar with access to additional funding, expertise, and resources. Collaborations could accelerate the development and commercialization of its MBTs. These partnerships could also validate CohBar's technology and increase its visibility within the industry. The timing of potential partnerships is uncertain, but could occur within the next 1-3 years.
• Growth opportunity 4: Expanding the pipeline of MBTs beyond the current programs could drive long-term growth. CohBar's expertise in mitochondrial biology could be leveraged to develop new therapies for other chronic and age-related diseases. This would require continued investment in research and development, but could create significant value over the long term. The timeline for developing new MBTs is typically 5-10 years.
• Growth opportunity 5: Securing orphan drug designation for its MBTs could provide CohBar with regulatory and commercial advantages. Orphan drug designation provides incentives such as market exclusivity and tax credits, making it more attractive to develop therapies for rare diseases. This could be particularly relevant for some of CohBar's preclinical programs. The timeline for obtaining orphan drug designation is typically 1-2 years.

What Are CWBR's Competitive Advantages?

• Proprietary technology platform based on mitochondria-derived peptides (MDPs).
• Patent protection for its MBTs and related technologies.
• Clinical trial data demonstrating the safety and efficacy of its MBTs.
• Expertise in mitochondrial biology and drug development.

What Does CWBR Do?

CohBar, Inc., founded in 2007 and headquartered in Menlo Park, California, is a clinical-stage biotechnology company dedicated to the research and development of mitochondria-based therapeutics (MBTs). These MBTs are designed to treat a range of chronic and age-related diseases, addressing significant unmet medical needs. The company's approach leverages the potential of mitochondrial-derived peptides (MDPs) to develop novel treatments. CohBar's lead clinical candidate, CB4211, a refined analog of the MOTS-c mitochondrial derived peptide, is currently in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. This trial aims to evaluate the safety and efficacy of CB4211 in these patient populations. In addition to CB4211, CohBar has several preclinical programs targeting other diseases. These include CB5138 analogs for fibrotic diseases and CB5064 analogs for COVID-19 associated ARDS. These programs reflect CohBar's commitment to expanding its pipeline and addressing a broad spectrum of medical conditions. CohBar's focus on MBTs differentiates it from other biotechnology companies, positioning it as a leader in this emerging field. The company's research and development efforts are geared towards translating scientific discoveries into innovative therapies that can improve patient outcomes.

What Products and Services Does CWBR Offer?

• Develop mitochondria-based therapeutics (MBTs) for chronic and age-related diseases.
• Focus on treating non-alcoholic steatohepatitis (NASH) and obesity.
• Research and develop therapies for fibrotic diseases.
• Explore treatments for COVID-19 associated ARDS.
• Utilize mitochondrial-derived peptides (MDPs) to develop novel treatments.
• Conduct clinical trials to evaluate the safety and efficacy of their MBTs.
• Seek strategic partnerships to accelerate development and commercialization.

How Does CWBR Make Money?

• Develop and patent novel mitochondria-based therapeutics (MBTs).
• Conduct preclinical and clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from agencies like the FDA.
• Potentially commercialize therapies directly or through partnerships.

What Industry Does CWBR Operate In?

CohBar operates within the biotechnology industry, which is characterized by intense competition, high R&D costs, and stringent regulatory requirements. The market for therapeutics targeting chronic and age-related diseases is substantial and growing, driven by an aging global population and increasing prevalence of conditions like NASH, obesity, and fibrotic diseases. CohBar's focus on mitochondria-based therapeutics (MBTs) positions it within a niche segment of the biotechnology industry. The company competes with other biotechnology and pharmaceutical companies developing treatments for these diseases. Success in this industry requires strong scientific expertise, effective clinical trial execution, and strategic partnerships.

Who Are CWBR's Key Customers?

• Patients suffering from chronic and age-related diseases such as NASH and obesity.
• Pharmaceutical companies seeking to license or acquire novel therapeutics.
• Healthcare providers who prescribe and administer treatments.

CWBR Valuation & Market Position

With a $1.19M market cap, CohBar, Inc. sits in the micro-cap segment of the market.

Return on equity for CohBar, Inc. stands at -58.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -73.1%, showing how much profit it generates from its asset base. A current ratio of 15.69 indicates the company holds enough short-term assets to cover its near-term obligations.

CohBar, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -13.78 places it in the distress zone, a signal of elevated financial risk.

CWBR Financials

CWBR Latest News

CWBR Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources